SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16703)3/4/2004 1:18:11 AM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Wow, that confirms these trials are a marketing tool. Expensive, kills market for 12 weeks but should be very effective as word of mouth plus getting trial participants as customers may makee it worth it.



To: Robert K. who wrote (16703)3/5/2004 1:13:01 PM
From: Bluegreen  Read Replies (1) | Respond to of 17367
 
So Bob, look at this. Does this mean the inflammatory response is WORSE than the active infection???? What would happen IF you added Raptiva to Synagis??? I wonder if Xoma or Genentech is even aware of this study???>>>>>>>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14990720&dopt=Abstract


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News